ChromaCode to Launch HDPCR™ Multiplexing Technology and Host Corporate Workshop at AMP 2018

CARLSBAD, Calif., Oct. 23, 2018 /PRNewswire/ -- ChromaCode, Inc., a company redefining molecular testing through data science, today announced it will introduce its High Definition Polymerase Chain Reaction (HDPCR™) multiplexing technology through a corporate workshop, exhibit hall booth (#327), and three study presentations during the upcoming Association for Molecular Pathology (AMP) 2018 Annual Meeting & Expo, taking place October 31 – November 3, 2018 in San Antonio, Texas.

ChromaCode's HDPCR™ multiplexing technology combines proprietary data science algorithms with widely-used, low-cost chemistries to enhance the multiplexing levels of common real-time and digital PCR instruments for detection of 5-50 targets in a single reaction. Through this application of data science, HDPCR™ empowers the enormous, global installed base of real-time and digital PCR instruments to perform multiplex testing at a very low cost.

"We continue to be impressed with the utility and flexibility of the HDPCR multiplexing technology," said Greg Tsongalis, Ph.D., Director, Laboratory for Clinical Genomics and Advanced Technology, Dartmouth Hitchcock Medical Center. "We've now generated compelling data using a single well, nine target proof-of-principle respiratory assay on our real-time PCR instrument as well as a single well, core trisomy non-invasive prenatal testing proof-of-principle panel on our digital PCR instrument. I'm excited to see ChromaCode continue work on commercializing these assays and feel they would provide much more cost-effective solutions than the multiplex PCR and NGS solutions currently available."

Two of the three HDPCR™ posters will review results from the development and preliminary analytical studies with the HDPCR Tick-Borne Pathogen Panel (Research Use Only; RUO), an instrument agnostic assay that targets nine of the most common tick-borne pathogens in a single reaction. 

"We were excited to evaluate the HDPCR Tick-Borne Pathogen Panel, as there is a gap in the market for a multiplex, molecular panel that detects common causes of tick-borne illness," said Blake Buchan, Ph.D., D(ABMM), Associate Professor, Department of Pathology, Medical College of Wisconsin and senior author of Abstract ID054. "The HDPCR technology is intriguing because, unlike all other multiplex technology, HDPCR can be performed on open real-time PCR instrumentation already in our lab, allowing us to avoid having to purchase expensive new instrumentation and spend resources for training on that instrument."

Corporate Workshop Details

• ChromaCode Corporate Workshop: "Multiplexing in the Digital Age: ChromaCode's Machine Learning-Based High-Definition PCR (HDPCR™) Technology"

Poster Presentation Details

• Abstract ID054: "Simultaneous Detection of Tickborne Pathogens Using a High Definition Multiplexed PCR Assay"

• Abstract ID057: "High-Definition PCR (HDPCR™): A Novel, Instrument Agnostic qPCR Multiplexing Technology Applied to Tick-Borne Pathogen Testing"

• Abstract TT069: "Comparison of Redundant Coding Vs. Binary Coding Scheme for Increased qPCR Multiplexing Levels and Improved Test Performance with ChromaCode's HDPCR Platform"

Please visit ChromaCode at Booth #327 in the Exhibit Hall during the conference to learn more about HDPCR™ technology.

About ChromaCode
Based in Carlsbad, CA, ChromaCode is redefining molecular testing through data science. ChromaCode's HDPCR™ multiplexing technology is the unique coupling of widely-used, low-cost chemistries with proprietary software using data science algorithms empowering the enormous, global installed base of real-time and digital PCR instrumentation to perform multiplex testing at a very low cost. Using HDPCR™, ChromaCode is seeking to expand global access to multiplex testing, reduce healthcare costs, and provide solutions for unmet healthcare needs faster.
www.ChromaCode.com

SOURCE ChromaCode, Inc.

Related Links

http://www.chromacode.com